Company Filing History:
1 out of 80 
1 out of 33 Years Active: 2004-2008
Title: Margo Honeyman: Innovator in Immunotherapy
Introduction
Margo Honeyman is a distinguished inventor based in St. Kilda, Australia. She has made significant contributions to the field of immunotherapy, particularly in relation to Insulin-Dependent Diabetes Mellitus (IDDM). With two patents to her name, her work focuses on developing diagnostic and therapeutic agents for this condition.
Latest Patents
Margo's latest patents include innovative molecules that interact immunologically with antibodies or T-cells in subjects with pre-clinical or clinical IDDM. The first patent, titled "Immunoreactive and immunotherapeutic molecules," describes peptides, polypeptides, and proteins that are preferentially immunoreactive to T-cells in individuals with IDDM. These molecules are crucial for the development of diagnostic, therapeutic, and prophylactic agents for the disease. Her second patent, "Immunoreactive peptides," shares similar objectives and highlights the importance of these molecules in advancing treatment options for IDDM.
Career Highlights
Throughout her career, Margo has worked with reputable organizations, including the Walter and Eliza Hall Institute of Medical Research and Amrad Corporation Limited. Her experience in these institutions has allowed her to refine her research and contribute to significant advancements in medical science.
Collaborations
Margo has collaborated with notable professionals in her field, including Leonard Charles Harrison and George Rudy. These partnerships have further enriched her research and innovation efforts.
Conclusion
Margo Honeyman's contributions to immunotherapy and her innovative patents position her as a key figure in the fight against Insulin-Dependent Diabetes Mellitus. Her work continues to inspire advancements in medical research and treatment options.